

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 0 963 983 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
15.12.1999 Bulletin 1999/50

(51) Int Cl.<sup>6</sup>: **C07D 401/14, A61K 31/44,  
A61K 31/445**

(21) Application number: **99303663.1**

(22) Date of filing: **11.05.1999**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

- **Gallagher, Peter Thaddeus**  
Windlesham, Surrey GU20 6PH (GB)
- **Miles, Martin Victor**  
Windlesham, Surrey GU20 6PH (GB)
- **Owton, William Martin**  
Windlesham, Surrey GU20 6PH (GB)
- **Smith, Colin William**  
Windlesham, Surrey GU20 6PH (GB)

(30) Priority: **13.05.1998 GB 9810886**


(71) Applicant: **ELI LILLY AND COMPANY LIMITED**  
**Basingstoke, Hants RG21 6XA (GB)**

(72) Inventors:  
• **Fairhurst, John**  
Windlesham, Surrey GU20 6PH (GB)

(74) Representative: **Hudson, Christopher Mark et al**  
**Eli Lilly and Company Limited,**  
**Lilly Research Centre,**  
**Erl Wood Manor**  
**Windlesham Surrey GU20 6PH (GB)**

(54) **Indol-2-ones as serotonin modulators**

(57) Pharmaceutical compounds of the formula:



(I)

in which

$n$  is 1 to 6,  $m$  is 1 or 2 and  $p$  is 1 or 2,

$R^1$  and  $R^2$  are each hydrogen,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $HO-C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy- $C_{1-4}$  alkyl,  $C_{1-4}$  alkylthio, halo, optionally substituted phenyl, optionally substituted phenyl- $C_{1-4}$  alkyl, or  $R^1$  and  $R^2$  together with the carbon atom to which they are attached form a  $C_{3-6}$  cycloalkyl group,  $>C=O$ ,  $C=NOR'$  where  $R'$  is hydrogen or  $C_{1-4}$  alkyl,

$R^3$ ,  $R^4$  and  $R^5$  are each hydrogen, halo, nitro,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkyl-CO-, where  $m$  is 0, 1 or 2,  $R'R''N$ - $SO_2$ -,  $-COOR'$ ,  $-CONR'R''$ ,  $-NR'R''$ ,  $-N(OR')COOR''$ ,  $-COR'$ ,  $-NHSO_2R'$ , where  $R'$  and  $R''$  are each hydrogen or  $C_{1-4}$  alkyl,

$R^6$  and  $R^7$  are each hydrogen or  $C_{1-4}$  alkyl.

**EP 0 963 983 A1**

**EP 0 963 983 A1**

X is oxygen or sulphur,

the dotted line represents an optional double bond, and the fluorine atom is attached at the 6- or 7-position; and salts thereof.

Compounds (I) are active at the serotonin, 5-HT<sub>2A</sub> receptor.


## Description

[0001] This invention relates to pharmaceutical compounds, their preparation and use.

[0002] Compounds of the indole-2-one type have been described in the literature as having potential use as analgesics or for treating cognitive disorders or as cholinesterase inhibitors as, for example, in J. Med. Chem. 1991, 34, 827-841, WO 93/12085 and CA 119: 225964t.

EP-A 0 780 388 discloses certain indole-2-one compounds with central nervous system properties.

[0003] The compounds of the invention are of the following formula:



in which n is 1 to 6, m is 1 or 2 and p is 1 or 2,

R<sup>1</sup> and R<sup>2</sup> are each hydrogen, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylthio, halo, optionally substituted phenyl, optionally substituted phenyl-C<sub>1-4</sub> alkyl, or R<sup>1</sup> and R<sup>2</sup> together with the carbon atom to which they are attached form a C<sub>3-6</sub> cycloalkyl group, >C=O, >C=NOR' where R' is hydrogen or C<sub>1-4</sub> alkyl,

R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each hydrogen, halo, nitro, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkyl-CO-, where m is 0, 1 or 2, R'R"N-SO<sub>2</sub>-, -COOR', -CONR'R", -NR'R", -N(OR')COOR", -COR', -NHSO<sub>2</sub>R', where R' and R" are each hydrogen or C<sub>1-4</sub> alkyl,

R<sup>6</sup> and R<sup>7</sup> are each hydrogen or C<sub>1-4</sub> alkyl,

X is oxygen or sulphur,

the dotted line represents an optional double bond, and

the fluorine atom is attached at the 6- or 7-position;

and salts thereof.

[0004] The compounds of the invention and their pharmaceutically acceptable salts are indicated for use in the treatment of disorders of the central nervous system. They are active in tests that indicate serotonergic modulation.

[0005] In the above formula (I), a C<sub>1-4</sub> alkyl group includes methyl, ethyl, propyl, isopropyl, butyl and tert. butyl, and is preferably methyl or ethyl. A C<sub>1-4</sub> alkoxy group is one such alkyl group linked to a ring via an oxygen atom, and a halo atom is preferably chlorine, bromine or fluorine, and especially chlorine or fluorine. A substituted phenyl group is phenyl substituted with one or more, for example one to three, substituents selected from, for example, C<sub>1-4</sub> alkyl, especially methyl, C<sub>1-4</sub> alkoxy, especially methoxy and ethoxy, hydroxy, nitro, cyano, halo, especially chloro or fluoro, trihalomethyl, especially trifluoromethyl, carboxy and C<sub>1-4</sub> alkoxy carbonyl. An optionally substituted phenyl-C<sub>1-4</sub> alkyl group is an optionally substituted phenyl attached through a C<sub>1-4</sub> alkyl group, and is preferably optionally substituted phenyl-(CH<sub>2</sub>)<sub>x</sub> where x is 1 or 2, and most preferably optionally substituted benzyl.

[0006] It will be appreciated that when n is more than one, the recurring unit is not necessarily the same.

[0007] Preferred compounds are those which exhibit one or more of the following features:

(i) the fluorine substituent is in the 6-position

(ii) x is oxygen

(iii) the dotted line represents a double bond

(iv) m is 2 and p is 1

(v) R<sup>1</sup> and R<sup>2</sup> are each hydrogen, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkylthio

(vi) R<sup>1</sup> and R<sup>2</sup> are both C<sub>1-4</sub> alkyl or benzyl

(vii) n is 2

(viii) R<sup>6</sup> and R<sup>7</sup> are hydrogen


(ix) R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each hydrogen.

[0008] As indicated above, it is, of course, possible to prepare salts of the compound of the invention and such salts are included in the invention. Acid addition salts are preferably the pharmaceutically acceptable, non-toxic addition salts with suitable acids, such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example, glycolic, maleic, hydroxy-maleic, fumaric, malic, tartaric, citric, salicylic, o-acetoxybenzoic, or organic sulphonic, 2-hydroxyethane sulphonic, toluene-p-sulphonic, or naphthalene-2-sulphonic acid.

[0009] In addition to the pharmaceutically acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically acceptable, acid addition salts, or are useful for identification, characterisation or purification.


[0010] Some of the compounds of the invention contain one or more asymmetric carbon atoms which gives rise to isomers. These compounds are normally prepared as racemic mixtures and can conveniently be used as such, but individual isomers can be isolated by conventional techniques, if so desired. Such racemic mixtures and individual optical isomers form part of the present invention. It is preferred to use an enantiomerically pure form.

[0011] A preferred group of compounds according to the invention is of formula:




in which R<sup>1</sup> and R<sup>2</sup> are each hydrogen or C<sub>1-4</sub> alkyl, and R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each hydrogen; and salts thereof.

[0012] The invention also includes a process for producing a compound of formula (I) above, which comprises reacting a compound of the formula:




15 with a compound of the formula:




35 where the substituents have the values given above, and X is a leaving group such as, for example, a halo atom, or a mesylate or tosylate. The coupling can also be effected by reacting the compound of formula (II) with an aldehyde equivalent of the compound of formula (III). Such aldehydes can be prepared from the appropriate terminal alkene by oxidation followed by reductive amination using sodium cyanoborohydride with the compound of formula (II).

40 [0013] The reaction is preferably carried out in a polar solvent such as, for example, acetonitrile or water, at a temperature of from 50° C. to 150° C., and in the presence of sodium iodide and a base such as, for example, sodium carbonate.

[0014] The intermediate compounds of formula (II) and formula (III) are known in the art. Compounds of formula (III) can be prepared by reacting the appropriate alkane derivative of formula:



where X is a leaving group and Y is halo, preferably bromo, with a compound of formula:



(V)

As mentioned above, the compounds of the invention and their pharmaceutically acceptable salts have useful central nervous system activity. The compounds are active at the serotonin, 5-HT<sub>2A</sub>, receptor. Their binding activity has been demonstrated in a test described by Leysen, J. E. et al., Molecular Pharmacology Vol. 21, 1981, pages 301-314, in which the affinity of the compound for the 2A receptor is measured by its ability to displace the ligand [<sup>3</sup>H] ketanserine. The compounds are also an active serotonin reuptake inhibitor as measured by its displacement of [<sup>3</sup>H] paroxetine at the reuptake site, Neuropharmacology Vol. 32 No. 8, 1993, pages 737-743.

**[0015]** Because of their selective affinity for 5-HT receptors, the compounds of the present invention are indicated for use in treating a variety of conditions such as depression, obesity, bulimia, alcoholism, pain, hypertension, ageing, memory loss, sexual dysfunction, anxiety, schizophrenia, gastrointestinal disorders, headache, cardiovascular disorders, smoking cessation, drug addiction, emesis, Alzheimer's and sleep disorders.

**[0016]** The compounds of the invention are effective over a wide dosage range, the actual dose administered being dependent on such factors as the particular compound being used, the condition being treated and the type and size of mammal being treated. However, the dosage required will normally fall within the range of 0.01 to 20 mg/kg per day, for example in the treatment of adult humans, dosages of from 0.5 to 100 mg per day may be used.

**[0017]** The compounds of the invention will normally be administered orally or by injection and, for this purpose, the compounds will usually be utilised in the form of a pharmaceutical composition. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.

**[0018]** Accordingly the invention includes a pharmaceutical composition comprising as active ingredient a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, associated with a pharmaceutically acceptable excipient. In making the compositions of the invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. The excipient may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Some examples of suitable excipients are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin syrup, methyl cellulose, methyl- and propyl-hydroxybenzoate, talc, magnesium stearate or oil. The compositions of the invention may, if desired, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.

**[0019]** Depending on the route of administration, the foregoing compositions may be formulated as tablets, capsules or suspensions for oral use and injection solutions or suspensions for parenteral use or as suppositories. Preferably the compositions are formulated in a dosage unit form, each dosage containing from 0.5 to 100 mg, more usually 1 to 100 mg, of the active ingredient.

**[0020]** The following Preparations and Examples illustrate methods of making compounds of the invention.

#### PREPARATIONS

##### [0021]

(1) N-Acetyl-1,3-dihydro-2H-indol-2-one: 1,3-Dihydro-2H-indol-2-one (35.6g, 0.268mol) suspended in acetic anhydride (30mls) and mixture refluxed for 20 hours. Filtered and washed with diethyl ether (50mls) dried in vacuo at 80degC to give a solid.

3-Spiro-1'-cyclopropyl-1,3-dihydro-2H-indol-2-one: N-Acetyl-1,3-dihydro-2H-indol-2-one (15.0g, 85.7mmols) dissolved in dimethylformamide (180mls) and added to suspension of sodium hydride (60% in oil dispersion, 7.2g, 4.32g, 0.18mol) in dimethylformamide (30mls). After 30 minutes 1,2-dibromoethane (17.71g, 94.27mmols) was

added and the mixture stirred at ambient temperature for 20 hours. More sodium hydride (1.4g, 0.84g, 14mmol) was added followed by 1,2-dibromoethane (4g, 21.96mmol) and stirred for 1h at ambient temperature. The solvent was removed in vacuo and the residue treated with water (100mls) added extracted with ethyl acetate (2x150mls), separated and dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo to give an oil which was purified by column chromatography on silica eluting with ethyl acetate/hexane to give 3-spiro-1'-cyclopropyl-1,3-dihydro-2H-indol-2-one as an oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 5.54 (2H m), 1.78 (2H m), 6.82 (1H d), 7.02 (2H m), 7.22 (1H m), 9.0 (1H broad)

(2) Cyclobutylphenylhydrazide : Phenylhydrazine (9.21g,

85.2mmols) was added to an ice bath cooled mixture of cyclobutane carbonyl chloride (10.1g, 85.2mmols) and triethylamine (8.62g, 85.2mmols) dissolved in dichloromethane (100mls) allowed to warm to ambient temperature and stirred for 48h. The organic layer was washed with water, separated, dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo. The resultant solid was washed with diethyl ether (10mls) and dried under suction to give a solid.

3-Spiro-1'-cyclobutyl-1,3-dihydro-2H-indol-2-one:

Cyclobutylphenylhydrazide (7.14g, 37.6mmols) combined with calcium hydride (2.37g) and heated to 240degC for 30 mins., cooled and methanol (40mls) and water (10mls) added followed by hydrochloric acid (d=1.16g/ml, 30mls) the resultant mixture heated under reflux for 1h., then basified with 5M sodium hydroxide to pH11 and the mixture extracted with diethyl ether. The ether layer was separated and dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo to give an oil which was chromatographed on silica eluting with ethyl acetate/hexane silica to give 3-spiro-1'-cyclobutyl-1,3-dihydro-2H-indol-2-one as an oil.

(3) 3-Spiro-1'-cyclopentyl-1,3-dihydro-2H-indol-2-one -

N-acetyl oxindole (5.0g, 28.6mmols) was dissolved in tetrahydrofuran (100mls) under nitrogen, cooled to -78C and 2.0M lithium diisopropylamide in THF (15.45ml, 30.9mmol) added and left to stir for 30mins. 1,4-dibromobutane (6.48g, 30mmols) added and mixture left for 1 hour at -78C. More lithium diisopropylamide in THF (15.45ml, 30.9mmol) added and the mixture left to warm to ambient temperature. The solvent was removed in vacuo and water (100mls) added, the aqueous extracted with ethyl acetate (2x150ml). The aqueous layer was separated, the organic layer dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo. The residue was purified by column chromatography on silica with ethyl acetate / hexane to give 3-spiro-1'-cyclopentyl-1,3-dihydro-2H-indol-2-one as an oil.

(4) Cyclohex-3,4-enylphenylhydrazide

A mixture of cyclohex-3-ene-1-carboxylic acid (15.23g, 0.120mols), and phenylhydrazine (13.16g, 0.122mols) dissolved in toluene (100mls) and heated under reflux for 18h with water separation using a Dean Stark apparatus. The toluene evaporated in vacuo and the residue recrystallised from diethyl ether to give a solid.

3-Spiro-1'-cyclohexyl-1,3-dihydro-2H-indol-2-one

To a -78C solution of 1,3-dihydro-2H-indol-2-one (10g, 75.1mmols) dissolved in tetrahydrofuran (200mls) was added lithium bis(trimethylsilyl)amide (1.0M in THF, 375mls, 0.375mol) was added keeping the temperature below -40C. The mixture was allowed to stir for 150 minutes at -40C cooled to -78C and 1,5-dibromopentane (86.35g 0.375mols) added. The reaction mixture was allowed to warm to ambient temperature and stirred for 3 hours then heated under reflux for 7 hours, concentrated in vacuo, dissolved in ethyl acetate (200mls) and washed with saturated aqueous ammonium chloride (100mls), dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo. The resultant solid was purified by chromatography (silica / ethyl acetate / hexane) to give 3-spiro-1'-cyclohexyl-1,3-dihydro-2H-indol-2-one as a solid.

(5) Methyl 2-nitrophenylacetate

A mixture of 2-nitrophenylacetic acid (300g, 1.66mol) and sulfuric acid (d=1.84g/ml, 6ml) in methanol (61) was heated under reflux for 21h. The solvent was removed in vacuo and the residue dissolved in dichloromethane (21). The dichloromethane solution was then washed with saturated aqueous sodium carbonate solution (600ml), brine (500ml), dried (MgSO<sub>4</sub>), filtered and then evaporated in vacuo.

Methyl 2-methyl-2-(2-nitrophenyl)propionate

Hexane (1000ml) was added to sodium hydride (60%, 180g, 4.5mol) and stirred under nitrogen for 5 minutes and then allowed to settle. The hexane was removed by decantation and replaced with dry dimethylformamide (31). More sodium hydride (unwashed 14g, 0.35mol) was then added and the reaction mixture was cooled to 5C and treated with methyl 2-nitrophenylacetate (323g 1.66mol) in dry dimethylformamide (1500ml) during 27mins whilst the internal temperature was kept below 5C. The mixture was then allowed to stir for 2h allowing the temperature to rise to ambient. The purple reaction mixture was then cooled to 0C and a solution of iodomethane (367ml, 5.8mol) in dry dimethylformamide was added dropwise during 38mins at 0-5C and maintained at this temperature for 45mins then allowed to warm to ambient temperature and stirred for 22h. The reaction mixture

was then poured onto ice (5kg) diluted with water (8000ml) stirred for 10mins and then extracted with diethyl ether (3x1500ml), the organic extracts combined filtered through celite, dried (MgSO<sub>4</sub>), filtered and evaporated in vacuo to give an oil which was used without further purification.

3,3-Dimethyl-1,3-dihydro-2H-indol-2-one

To a well stirred mixture of iron powder (476g, 8.52mol) in acetic acid (3000ml) at 92°C under nitrogen was added dropwise during 40mins a solution of methyl 2-methyl-2-(2-nitrophenyl)propionate (395g, 1.77mol) in acetic acid (500ml). The resultant exothermic reaction was maintained at 100°C for 15 mins cooled to 30°C, filtered and the filtered iron washed with acetic acid, combined with the reaction mixture and evaporated in vacuo to give a residue which was dissolved in ethyl acetate and then washed with hydrochloric acid (1000ml), brine (1000ml), dried (MgSO<sub>4</sub>) filtered and evaporated in vacuo to give a crystalline solid.

(6) 3-Methyl-3-methylthio-1,3-dihydro-2H-indol-2-one:

1,3-Dihydroindol-2(3H)-one (3.3g, 25mmol) and tetramethylethylenediamine (6.4g, 55mmol) was dissolved in freshly distilled tetrahydrofuran under nitrogen and cooled to -75°C. in an acetone/dry ice bath. n-Butyllithium (2.5M, 22ml, 55mmol) was added and the mixture was stirred at -75°C. for 30 minutes. Iodomethane (3.57g, 25mmol) was added and the mixture was allowed to warm to -20°C., the mixture was recooled to -75°C. then dimethyl disulfide (2.35g, 25mmol) was added and the mixture was allowed to warm to room temperature. Water (5 ml) was added and the mixture was concentrated under reduced pressure to a yellow oil. Column chromatography on silica gel (eluent ethyl acetate/hexane) gave 3-methyl-3-methylthio-1,3-dihydro-2H-indol-2-one as a yellow oil which solidified on standing.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.61(3H s), 1.91(3H s), 6.96(1H d), 7.04(1H t), 7.12(2H m), 8.05 (1h broad).

(7) 5-Bromo-3,3-dimethyl-1,3-dihydro-2H-indol-2-one :

3,3-dimethyl-1,3-dihydro-2H-indol-2-one (1.12g, 6.95mmol) was dissolved in chloroform and stirred at room temperature under nitrogen. Bromine (1.12g) was added and the mixture was heated under reflux until HBr evolution ceased and the bromine colour was discharged from the solution. The solution was washed with sodium metabisulphite solution and sodium hydrogen carbonate solution, dried (MgSO<sub>4</sub>), filtered and concentrated to dry under reduced pressure to give 5-bromo-3,3-dimethyl-1,3-dihydro-2H-indol-2-one as a yellow solid.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.39 (6H s), 6.8 (1H d), 7.3 (2H m), 7.9 (1H broad)

(8) 5,6-Difluoro-1,3-dihydro-2H-indol-2-one: 3,4-

Difluoroacetonitrile (5g, 32.7mmol) was added dropwise to 90% fuming nitric acid (25ml) stirred and cooled in an ice/water bath. After 15 hours' stirring the mixture was poured into water, neutralised with sodium bicarbonate and extracted into dichloromethane. The organic phase was dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure. The resulting oil was dissolved in boron trifluoride acetic acid complex (30ml), water (1 ml) was added and the mixture was heated under reflux for three hours. The mixture was poured into water, the pH was adjusted to pH4 and the mixture was extracted with ethyl acetate. The organic phase was dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure. The resulting oily solid was dissolved in acetic acid, iron powder was added and the mixture was heated under reflux for 1 hour. The mixture was filtered through Celite and concentrated under reduced pressure to a dark oil. Column chromatography on silica gel (eluent chloroform/methanol) gave 5,6-difluoro-1,3-dihydro-2H-indol-2-one as an orange solid.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.48(2H s), 6.7(1H dd), 7.05(1H dd), 8.65(1H broad)

(9) 3,3,4-Trimethyl-1,3-dihydro-2H-indol-2-one and 3,3,6-Trimethyl-1,3-dihydro-2H-indol-2-one :

Prepared from N-isobutyl-3-methylphenylhydrazide by the method of Endler and Becker, Organic Syntheses Coll. vol. 4 page 657 and separated by preparative HPLC.

Melting point 3,3,4-Trimethyl-1,3-dihydro-2H-indol-2-one -133° C.

Melting point - 3,3,6-Trimethyl-1,3-Dihydro-2H-indol-2-one -178° C.

(10) 3,3-Dimethyl-1-(2-hydroxy-1-ethyl)-1,3-dihydro-2H-indol-2-one : 3,3-Dimethyl-1,3-dihydro-2H-indol-2-one (6.3g, 40mmol) was dissolved in dry dimethylformamide under nitrogen at room temperature. Sodium hydride (60% dispersion in mineral oil, 1.8g, 45mmol) was added and the mixture was stirred until gas evolution ceased. 2-(2-Chloroethoxy)tetrahydro-2H-pyran (7.5g, 42mmol) and sodium iodide (0.6g, 4mmol) was added and the mixture was warmed to 75° C for 15 hours. Water was added and the mixture was concentrated under reduced pressure. The residue was taken up in ethyl acetate, washed (x 3) with water, dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure. The resulting oil was taken up in methanol, para toluenesulphonic acid (0.75g, 4mmol) was added and the mixture was stirred at room temperature for 12 hours. The mixture was concentrated under reduced pressure, taken up in ethyl acetate, washed (x 3) with aqueous sodium hydrogen carbonate solution dried



(MgSO<sub>4</sub>), filtered and concentrated under reduced pressure. The resulting oil was purified by chromatography on silica gel, eluent hexane/ethyl acetate, to give 3,3-dimethyl-1-(2-hydroxy-1-ethyl)-1,3-dihydro-2H-indol-2-one which was characterised by <sup>1</sup>H nmr and MS.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.4(6H s), 3.05 (1H broad), 3.95(4H s), 6.96(1H d), 7.04(1H t), 7.12(2H m).

MS shows 206 (MH<sup>+</sup>) base peak.

(11) 1-(2-Hydroxy-1-ethyl)-3-methyl-3-methylthio-1,3-dihydro-2H-indol-2-one:

Prepared from 3-methyl-3-methylthioindol-2(3H)-one and 2-(2-chloroethoxy)tetrahydro-2H-pyran as described for 3,3-dimethyl-1-(2-hydroxy-1-ethyl)-1,3-dihydro-2H-indol-2-one.

MS shows 238 (MH<sup>+</sup>) base peak.

(12) 3-Ethyl-1-(2-hydroxy-1-ethyl)-3-methyl-1,3-dihydro-2H-indol-2-one:

Prepared from 3-ethyl-3-methylindol-2(3H)-one (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657) and 2-(2-chloroethoxy)tetrahydro-2H-pyran as described in above.

MS shows 220 (MH<sup>+</sup>) base peak.

(13) 5-Bromo-3,3-dimethyl-1-(2-hydroxy-1-ethyl)-1,3-dihydro-2H-indol-2-one :

Prepared from 5-bromo-3,3-dimethyl-1,3-dihydro-2H-indol-2-one and 2-(2-chloroethoxy)tetrahydro-2H-pyran as described above.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.39 (6H s), 3.05 (1H broad), 3.95(4H s), 6.8 (1H d), 7.3 (2H m),

(14) 1-(2-Hydroxy-1-ethyl)-3,3,5-trimethyl-1,3-dihydro-2H-indol-2-one :

Prepared from 3,3,5-trimethyl-1,3-dihydro-2H-indol-2-one (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657) and 2-(2-chloroethoxy)tetrahydro-2H-pyran as described above.

MS shows 220 (MH<sup>+</sup>) base peak and 237 (M+NH<sub>4</sub>)

(15) 5-Chloro-3,3-dimethyl-1-(2-hydroxy-1-ethyl)-1,3-dihydro-2H-indol-2-one :

Prepared from 5-chloro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4, page 657) and 2-(2-chloroethoxy)tetrahydro-2H-pyran as described above.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.39 (6H s), 3.05 (1H broad), 3.95(4H s), 6.8 (1H d), 7.3 (2H m),

(16) 1-(2-Hydroxy-1-ethyl)-3,3,7-trimethyl-1,3-dihydro-2H-indol-2-one :

Prepared from 3,3,7-trimethyl-1,3-dihydro-2H-indol-2-one (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657) and 2-(2-chloroethoxy)tetrahydro-2H-pyran as described above.

MS shows 220 (MH<sup>+</sup>) base peak and 237 (M+NH<sub>4</sub>)

(17) 3,3-Dimethyl-1-(2-hydroxy-1-ethyl)-5-methoxy-1,3-dihydro-2H-indol-2-one:

Prepared from 3,3-dimethyl-5-methoxy-1,3-dihydro-2H-indol-2-one (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657) and 2-(2-chloroethoxy)tetrahydro-2H-pyran as described above.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.39 (6H s), 3.05 (1H broad), 3.82(3H s), 3.95(4H s), 6.8 (1H d), 7.3 (2H m),

(18) 1-(2-Hydroxy-1-ethyl)-3,3,4-trimethyl-1,3-dihydro-2H-indol-2-one :

Prepared from 3,3,4-trimethyl-1,3-dihydro-2H-indol-2-one (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4, page 657) and 2-(2-chloroethoxy)tetrahydro-2H-pyran as described above.

MS shows 220 (MH<sup>+</sup>) base peak and 237 (M+NH<sub>4</sub>)

(19) 1-(2-Hydroxy-1-ethyl)-3,3,6-trimethyl-1,3-dihydro-2H-indol-2-one:

Prepared from 3,3,6-trimethyloxindole (prepared by the method of Endler and Becker; Organic Syntheses Coll. vol. 4 page 657) and 2-(2-chloroethoxy)tetrahydro-2H-pyran as described above.

MS shows 220 (MH<sup>+</sup>) base peak and 237 (M+NH<sub>4</sub>)

(20) 1-(2-Hydroxy-1-ethyl)-3-spiro-1'-cyclopropyl-1,3-dihydro-2H-indol-2-one:

Prepared from 3-spiro-1'-cyclopropyl-1,3-dihydro-2H-indol-2-one and 2-(2-chloroethoxy)tetrahydro-2H-pyran.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.54 (2H m), 1.78 (2H m), 3.85 (4H m), 6.82 (1H d), 7.02 (2H m), 7.22 (1H m)

(21) 1-(2-Hydroxy-1-ethyl)-3-spiro-1'-cyclopentyl-1,3-dihydro-2H-indol-2-one

60% Sodium Hydride in oil dispersion (0.132g, 3.29mmols) was added to 3-spiro-1'-cyclopentyl-1,3-dihydro-2H-indol-2-one (0.513g, 2.74mmols) dissolved in N-methylpyrrolidinone (5ml) followed by chloroethyl tetrahydro-

pyran (0.541g, 3.29mmols) and the resultant mixture heated to 80°C for 12h. The mixture was cooled, water (30ml) was added and the product extracted into ethyl acetate (2x75ml), dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo to give an oil. To this residue was added methanol (20mls) and para-toluenesulfonic acid (0.08g) and the mixture stirred at ambient temperature for 16h. The solvent was evaporated in vacuo and the resulting oil was purified by column chromatography on silica with ethyl acetate/hexane to give an oil.

(22) 5-Fluoro-1-(2-hydroxy-1-ethyl)-1,3-dihydro-2H-indol-2-one:

5-Fluoro-1,3-dihydro-2H-indol-2-one (2.4g, 15.9mmol) (prepared according to the method of Clark et al., Synthesis (1991) 871) was dissolved in freshly distilled tetrahydrofuran with tetramethylethylenediamine (3.7g, 31.9mmol) and was cooled to -75° C. under nitrogen. n-Butyllithium (2.4 equivalents) was added and the mixture was stirred at -75° C. for 40 minutes. Iodomethane (9g, 63mmol) was added and the mixture was allowed to warm to room temperature. After two hours' stirring at this temperature, water (5 ml) was added and the mixture was concentrated under reduced pressure, the resulting oil was taken up in dichloromethane, washed with dilute hydrochloric acid, dried (MgSO<sub>4</sub>), filtered and concentrated to dry under reduced pressure to give a yellow oil. This oil was dissolved in N-methylpyrrolidone and stirred at room temperature under nitrogen. Sodium hydride (0.625g, 15.6mmol) was added and the mixture was stirred until gas evolution ceased. 2-(2-Chloroethoxy)tetrahydro-2H-pyran (2.5g, 15mmol) and sodium iodide (0.1g, 0.66mmol) was added and the mixture was warmed to 75°C. for 15 hours. Water was added and the mixture was concentrated under reduced pressure. The residue was taken up in ethyl acetate, washed (x3) with water, dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure. The resulting oil was taken up in methanol, para toluenesulphonic acid (0.1g, 0.5mmol) was added and the mixture was stirred at room temperature for 12h. The mixture was concentrated under reduced pressure, taken up in ethyl acetate, washed (x 3) with aqueous sodium hydrogen carbonate solution dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure. The resulting oil was purified by column chromatography on silica gel, (eluent hexane/ethyl acetate) to give 5-fluoro-1-(2-hydroxy-1-ethyl)-1,3-dihydro-2H-indol-2-one as a yellow oil. MS shows 224 (MH<sup>+</sup>) base peak and 241 (M+NH<sub>4</sub>)

(23) 5,6-Difluoro-3,3-dimethyl-1-(2-hydroxy-1-ethyl)-1,3-dihydro-2H-indol-2-one:

Prepared from 5,6-difluoro-1,3-dihydro-2H-indol-2-one and converted to 5,6-difluoro-3,3-dimethyl-1-(2-hydroxy-1-ethyl)-1,3-dihydro-2H-indol-2-one as described for the synthesis of 3,3-dimethyl-5-fluoro-1-(2-hydroxy-1-ethyl)-1,3-dihydro-2H-indol-2-one.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.38(6H s), 3.20(1H broad), 3.84(4H m), 6.7(1H dd), 7.03(1H dd)

(24) 1-(2-Chloroethyl)-1,3-dihydro-2H-indol-2-one :

1-(2-Chloroethyl)-1H-indole-2,3-dione [C.A. Reg no. 77218-99-6] was suspended in acetic acid and hydrogenated at 60 p.s.i., at room temperature, in the presence of 70% perchloric acid and 5% palladium on charcoal for 24h. The clear solution was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel, eluent chloroform, to give 1-(2-chloroethyl)-1,3-dihydro-2H-indol-2-one as a white solid, melting point 74°C.

(25) 1-(2-Chloro-1-ethyl)-5-fluoro-1H-indole-2,3-dione :

5-Fluoro-1H-indole-2,3-dione was dissolved in dimethylformamide. Sodium hydride (60% dispersion in mineral oil)(1.2 equivalents) was added in portions with stirring and cooling (ice-water bath) and the mixture was stirred until gas evolution ceased. 1-Bromo-2-chloroethane (1.2 equivalents) was added dropwise. The mixture was stirred at room temperature for 24 hours and then quenched into water and extracted into chloroform. The combined organic phases were washed with water, dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure. The resulting oil was purified by chromatography on silica gel, eluent chloroform, to give 1-(2-chloro-1-ethyl)-5-fluoro-1H-indole-2,3-dione as a red solid. Melting point 103° C.

(26) 1-(2-Chloro-1-ethyl)-1,3-dihydro-5-fluoro-2-oxo-2H-indole-3-spiro-2'-1,3 dithiane

A solution of 1-(2-chloro-1-ethyl)-5-fluoro-1H-indole-2,3-dione, propanedithiol (1.2 equivalents) in chloroform was added dropwise to a stirred solution of boron trifluoride etherate in acetic acid and chloroform which was maintained at a gentle reflux throughout the addition. After 6 hours' reaction the mixture was cooled, washed with water and sodium hydrogen carbonate solution, dried (MgSO<sub>4</sub>) and filtered through a pad of flash silica using chloroform as eluent. The combined fractions were evaporated under reduced pressure to give 1-(2-chloro-1-ethyl)-1,3-dihydro-5-fluoro-2-oxo-2H-indole-3-spiro-2'-1,3 dithiane. Melting point 122° C.

(27) 1-(2-Chloro-1-ethyl)-5-fluoro-1,3-dihydro-2H-indole-2-one:

1-(2-chloro-1-ethyl)-1,3-dihydro-5-fluoro-2-oxo-2H-indole-3-spiro-2'-1,3 dithiane was dissolved in a mixture of ethanol/tetrahydrofuran (3:2). Raney nickel was added and the mixture was heated under reflux with vigorous stirring for 3h. The cooled solution was filtered, evaporated under reduced pressure and triturated with ether to give 1-(2-chloro-1-ethyl)-5-fluoro-1,3-dihydro-2H-indole-2-one as a white solid, melting point 127° C.

(28) 1-(2-Chloro-1-ethyl)-3,3-difluoro-1,3-dihydro-2H-indole-2-one:

1-(2-Chloro-1-ethyl)-1H-indole-2,3-dione (1.1g, 5.2mmol) [C. A. Reg no. 77218-99-6] was heated to 65°C under nitrogen in diethylaminosulfur trifluoride (3ml). The reaction mixture was poured onto water and extracted with chloroform. The organic phase was washed with sodium hydrogen carbonate solution, dried (MgSO<sub>4</sub>) and filtered to give 1-(2-chloro-1-ethyl)-3,3-difluoro-1,3-dihydro-2H-indole-2-one as a dark oil. MS shows 231 and 233 (MH<sup>+</sup>)

(29) 1-(2-Chloro-1-ethyl)-3,3,5-triifluoro-1,3-dihydro-2H-indole-2-one:

Prepared from 1-(2-chloroethyl)-5-fluoro-1H-indole-2,3-dione and diethylaminosulfur trifluoride. MS shows 249 and 251 (MH<sup>+</sup>)

(30) 1-(2-Chloro-1-ethyl)-3-spiro-1'-cyclohexyl-1,3-dihydro-2H-indol-2-one

60% Sodium hydride in oil dispersion (0.46g, 11.46mmols) added was added to 3-spiro-1'-cyclohexyl-1,3-dihydro-2H-indol-2-one (1.922g, 9.55mmols) dissolved in dimethylformamide (25mls) followed by bromochloroethane (1.643g, 11.46mmols) and the resultant mixture stirred for 2 hours at ambient temperature. Water (30mls) was added and the product extracted into ethyl acetate (2x75ml) the ethyl acetate layer dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo. The resulting oil purified by column chromatography on silica with ethyl acetate / hexane to give an oil).

(31) 3,3-Dimethyl-1-(2-methanesulfonyloxy-1-ethyl)-1,3-dihydro-2H-indol-2-one

Sodium hydride (60% oil dispersion, 2.98g, 74.4 mmol) was washed with hexane, the hexane decanted and replaced with dimethylformamide (30ml). To this mixture was added dropwise during 30mins with stirring under nitrogen at ambient temperature 3,3-dimethyl-1,3-dihydro-2H-indol-2-one (10g, 0.062mol) in dimethylformamide (220ml). This mixture was stirred for 1h at ambient temperature then 2-(2-chloroethoxy)-2-tetrahydro-2H-pyran (12.25g) was added in one portion. The mixture was heated to 80°C for 1.25h then poured into water (750ml) and extracted with ethyl acetate (3x200ml). The combined extracts were washed with water, dried (MgSO<sub>4</sub>), filtered, and the filtrate evaporated in vacuo to give an oil 24.6g, which was dissolved in methanol (50ml) and treated with para-toluenesulfonic monohydrate (1.6g, 8.4mmol) and stirred for 16h, at ambient temperature under nitrogen. The solvent was removed in vacuo and the residue dissolved in ethyl acetate and washed with aqueous potassium carbonate solution (2x), dried (MgSO<sub>4</sub>), filtered, and evaporated in vacuo to give an oil 15.1g which was dissolved in dichloromethane (75ml) and triethylamine (9.41g 93mmol) was added followed by dropwise addition of methanesulfonyl chloride (6.0ml, 77.5mmol) during 4 mins and then stirred for 1.25h. The solvent was then evaporated in vacuo and the residue partitioned between ethyl acetate and water, the organic extract washed with brine, dried (MgSO<sub>4</sub>), filtered, and the filtrate evaporated in vacuo to give an oil 18.8g. This oil was triturated with a small quantity of diethyl ether and the resultant cream coloured precipitate isolated by filtration and dried in vacuo to give a solid 13.16g. Further purification was effected by trituration with warm diethyl ether to give a solid.

(32) 1-(2-Methanesulfonyloxy-1-ethyl)-3-spiro-1'-cyclopentyl-1,3-dihydro-2H-indol-2-one:

Triethylamine (0.246g, 2.43mmols) was added to 1-(2-hydroxy-1-ethyl)-3-spiro-1'-cyclopentyl-1,3-dihydro-2H-indol-2-one (0.433g, 1.87mmols) dissolved in dichloromethane (10mls) followed by methanesulfonyl chloride (0.16mls 2.06mmols) and the mixture stirred at ambient temperature for 3 hours. Water was added (20mls) the dichloromethane layer separated and dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo to give a solid.

(33) 1-Dimethylamino-2-(4-fluoro-2-nitro)phenylethene

A mixture of 4-fluoro-2-nitrotoluene (50g, 0.32mol), dimethylformamide dimethylacetal (76.77g) and dimethylformamide (910ml) were heated under reflux under nitrogen with stirring for 7h, cooled allowed to stand for 16h, poured into ice-water (2000ml), stirred for 15mins, the resultant precipitate isolated by filtration, washed with water (500ml), dried to give a red solid.

(34) 6-Fluoroindole

A 40 litre Cook hydrogenator was charged under a nitrogen atmosphere with 10% palladium on charcoal (9g) suspended in toluene (400ml). To this suspension was added 1-dimethylamino-2-(4-fluoro-2-nitro)phenylethene (137.2g, 0.653mol) in toluene (1400ml) and the mixture hydrogenated at 80psifor 3.5h. The suspension was then

filtered through a celite pad, which was washed through with toluene (2x200ml) and the filtrate and washings evaporated under reduced pressure to give a brown oil which crystallised on standing to a yellow brown solid 93.65g. This solid was dissolved in ethyl acetate-hexane (7:3) and filtered through a pad of flash silica. The required fractions were collected and evaporated under reduced pressure to give a pale brown solid.

Similarly prepared was 6-Cyanoindole.

(35) 7-Fluoroindole

2-Fluoronitrobenzene (20.0g, 0.142mols) dissolved in dry tetrahydrofuran (400mls) and cooled to -50degC. Vinylmagnesium chloride (288mls, 15%wt/vol) added at -45degC and stirred at this temperature for one hour. Poured onto saturated ammonium chloride (600mls). Separated and aqueous extracted with diethyl ether (2x200mls). Dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo to yield a dark oil which was purified column chromatography on silica using toluene as mobile phase. Fractions concentrated to yield a crystalline solid. Similarly prepared was 6-Fluoro-7-methylindole.

(36) 7-Fluoroindole

To a stirred solution of boron trichloride in dichloromethane (1.0M, 3.6501, 3.65mol) at -10C under nitrogen was added 2-fluoroaniline (387g, 3.48mol) and the temperature rose to 18C. The mixture was stirred for 45 mins before chloroacetonitrile (300g, 3.97mol) followed by aluminium chloride (500g, 3.75mol). 1,2-Dichloroethane (5.71) was added the mixture heated and the dichloromethane distilled from the reaction vessel. The dichloroethane solution was then heated at 78-80C for 18h. The reaction mixture was then cooled to 2C and hydrochloric acid (2.5M 450ml) was added slowly with a resultant exotherm. More hydrochloric acid (2.5M, 5.5501) was added and then the mixture was warmed to reflux for 10mins then cooled. The dichloroethane layer was separated and the aqueous layer extracted with dichloromethane (11) combined with the dichloroethane, washed with brine (21), dried (MgSO<sub>4</sub>), filtered and the solvent evaporated in vacuo to give a solid 321.7g. This solid was dissolved in a mixture of dioxan (101) and water (11) and treated under nitrogen with sodium borohydride (73.0g, 1.93mol) then heated under reflux for 1h. More sodium borohydride (12g) was added and the mixture heated for a further 3h, cooled to 45C and the solvent removed in vacuo. The residue was partitioned between dichloromethane (2000ml) and water (2000ml). The organic layer was separated, dried (MgSO<sub>4</sub>), filtered and evaporated in vacuo to give an oil which was further purified by filtering through silica.

Similarly prepared was 6,7-Difluoroindole.

(37) 5,6-Difluoroindole

Fuming nitric acid (25ml) was stirred with cooling (ice/water bath) and 3,4-difluorophenylacetonitrile (5g, 32.7mmol) was added dropwise. The mixture was left to stir for 15h and was then poured onto ice. The mixture was neutralised with sodium hydrogen carbonate and extracted with dichloromethane. The combined organic phases were dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure to give 2-(2'-nitro-4',5'-difluorophenyl)-acetonitrile as a yellow oil which was immediately in ethanol/acetic acid (19:1) and hydrogenated over 10% palladium on charcoal at 65 p.s.i. The reaction mixture was filtered and concentrated under reduced pressure. The oily residue was taken up in ethyl acetate and washed with aqueous sodium hydrogen carbonate solution. The combined organic phases were dried (MgSO<sub>4</sub>), filtered and concentrated under reduced pressure to give 5,6-Difluoroindole as a yellow solid. Mass spectroscopy showed 154.1 (MH<sup>+</sup>).

(38) 4-(6-Fluoroindol-3-yl)-1,2,5,6-tetrahydropyridine

Powdered potassium hydroxide (144.4g) was added carefully to a mechanically stirred mixture of 6-fluoroindole (49.23g, 0.364mol) and piperidine monohydrate (111.93g, 0.728mol) in methanol (1500ml) The mixture was then heated under reflux under nitrogen for 18h and then more potassium hydroxide (40g) was added and the reaction mixture heated under reflux for a further 4h. The reaction mixture was allowed to cool to room temperature and poured onto ice-water (3000ml) and stirred for 1h and the precipitated solid isolated by filtration and dried at 50C in vacuo to give a solid.

(39) 4-(6-Fluoroindol-3-yl)piperidine

A mixture of platinum oxide (1.0g) in ethanol (37.5ml) and glacial acetic acid (12.5ml) was treated under nitrogen with 4-(6-fluoroindol-3-yl)-1,2,5,6-tetrahydropyridine (20g, 92.6mmol) in ethanol (187.5ml) and glacial acetic acid (62.5ml). The nitrogen was evacuated and hydrogen was admitted. The reaction mixture was then hydrogenated at 60psi until the reaction was complete by tic. The catalyst was removed by filtration and the solvent evaporated in vacuo to give a yellow solid which after drying at 60C in vacuo weighed.

EXAMPLE 13,3-Dimethyl-1-{2-[4-(7-fluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one

**[0022]** 4-(7-Fluoroindol-3-yl)-1,2,5,6-tetrahydropyridine (2.0g, 9.26mmols), 3,3-dimethyl-1-(2-methanesulfonyloxy-1-ethyl)-1,3-dihydro-2H-indol-2-one (2.623g, 9.26mmols), sodium carbonate (2.947g, 27.8mmols), water (20mls) combined and heated to 90degC for 3 hours. Extracted into ethyl acetate (2x50ml). Dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo. The resultant solid was recrystallised from ethyl acetate and then converted to the hydrochloride salt (0.85g). m.p 235-236 degC

EXAMPLE 23,3-Dimethyl-1-{2-[4-(6-fluoro-7-methylindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one hydrochloride.

**[0023]** 3,3-dimethyl-1-(2-methanesulfonyloxy-1-ethyl)-1,3-dihydro-2H-indol-2-one (6.21g, 0.0219mols) and 4-(6-fluoro-7-methylindol-3-yl)-1,2,5,6-tetrahydropyridine (5.05g, 0.0219mols) were dissolved in dry acetonitrile (220 mL). To this potassium carbonate (3.5g, 0.026mol) and potassium iodide (4.23g, 0.026 mol) were added. The mixture was stirred, whilst heating under reflux, for 4h. The hot mixture was filtered off from inorganic material after this time and the filtrate was evaporated to dryness *in vacuo*. The residue was dissolved in chloroform, to which a minimum of methanol was added to aid solubility and filtered off from any remaining inorganic materials. This filtrate was column chromatographed using initially chloroform with "flash" silica gel as the stationary phase. The bulk of the material was eluted using 2% methanol in chloroform, any remaining material was removed with 5% methanol in chloroform.

**[0024]** The fractions containing product were bulked and evaporated to dryness, *in vacuo*, the residue was triturated with ethyl acetate, filtered off and dried in a vacuum oven at 60°C. The weight of freebase = 6.81g, melting point = 219°C. This material (1g) was dissolved in boiling ethyl acetate (100mL) and enough ethanolic hydrogen chloride was added to this solution to render it acid when tested with pH paper. The solution was chilled and a hydrochloride salt crystallised out. The salt was filtered off, washed with ethyl acetate, ether, and dried, melting point = 228.8-233.3°C.

EXAMPLE 33,3-Dimethyl-1-{2-[4-(7-fluoroindol-3-yl)-1-piperidinyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one Monohydrochloride

**[0025]** 3,3-Dimethyl-1-{2-[4-(7-fluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one (0.6g, 1.36mmol) dissolved in ethanol (40mls) and acetic acid (4mls) was added to 10% platinum oxide/charcoal. Hydrogen was admitted for 12h at 60psi the catalyst was then removed by filtration, the catalyst washed with ethanol (3x75mls), concentrated in vacuo and the resulting oil purified by column chromatography on silica with ethyl acetate/Hexane. The fractions containing product were collected and the solvent evaporated in vacuo to give a solid which was converted to the hydrochloride, which was subsequently dried in vacuo to give a solid, mp 172-174°C

EXAMPLE 43,3-Dimethyl-1-{2-[4-(6-fluoroindol-3-yl)-1-piperidinyl]-1-ethyl}-1,3-dihydro-2H-indol-2-thione Monohydrochloride

**[0026]** Phosphorus pentasulfide (0.164g) was added to 3,3-dimethyl-1-{2-[4-(6-fluoroindol-3-yl)-1-piperidinyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one (0.5g, 1.23mmol) dissolved in pyridine (15mls) and the mixture heated under reflux for 12 hours. The resultant mixture concentrated in vacuo and dissolved in ethyl acetate (50mls) and washed with water (50ml). The ethyl acetate layer dried (MgSO<sub>4</sub>), filtered and concentrated in vacuo to give a solid which was purified by column chromatography using silica / dichloromethane then ethyl acetate. The fractions containing product were concentrated and converted to the hydrochloride salt, mp 227-229°C.

**[0027]** Similarly prepared were:

3,3-Dimethyl-N,N-dimethyl-1-{2-[4-(6-fluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-2-oxo-indole-5-carboxamide hydrochloride. mp = 210.2-215°C

1-{2-[4-(6-Chloroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-3,3-dimethyl-N,N-dimethyl-1,3-dihydro-2H-2-oxo-indole-5-carboxamide. mp = 225°C

3,3-Dimethyl-1-{2-[4-(7-chloroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 248.9-249.9°C

5 3,3-Dimethyl-1-{2-[4-(6-fluoro-7-methylindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 228.8-233.3°C

1-{2-[4-(6,7-Difluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-3,3-dimethyl-5-fluoro-1,3-dihydro-2H-indol-2-one hydrochloride. mp >250°C

10 3,3-Dimethyl-5,6-difluoro-1-{2-[4-(6-fluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 227-229°C

15 1-{2-[4-(6-Fluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-3-methyl-3-methylthio-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 165-168°C

1-{2-[4-(6-Fluoroindol-3-yl)-1-piperidinyl]-1-ethyl}-3,3,5-trimethyl-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 220-222°C

20 5,6-Difluoro-3,3-dimethyl-1-{2-[4-(6-fluoroindol-3-yl)-1-piperidinyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 231-233°C

3,3-Dimethyl-1-{2-[4-(6-fluoro-1-methylindol-3-yl)-1-piperidinyl]-1-ethyl}-5-methoxy-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 252-255°C

25 3-Ethyl-1-{2-[4-(6-fluoroindol-3-yl)-1-piperidinyl]-1-ethyl}-3-methyl-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 221-223°C

3,3-Dimethyl-5-fluoro-1-{2-[4-(6-fluoro-1-methylindol-3-yl)-1-piperidinyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one hydrochloride. mp >260°C

30 1-{2-[4-(5,6-Difluoroindol-3-yl)-1-piperidinyl]-1-ethyl}-3,3-dimethyl-1,3-dihydro-2H-indol-2-one hydrochloride. mp >260°C

35 3-Ethyl-1-{2-[4-(6-fluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-3-methyl-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 196-204°C

1-{2-[4-(6-Fluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-3,3,5-trimethyl-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 206-222°C

40 3,3-Dimethyl-5-fluoro-1-{2-[4-(7-fluoroindol-3-yl)-1-piperidinyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 198-200°C

45 5-Chloro-3,3-dimethyl-1-{2-[4-(6-fluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 233.9-236.2°C

1-{2-[4-(6,7-Dichloroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-3,3-dimethyl-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 262-266°C

50 1-{2-[4-(5,7-Difluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-3-spiro-4'-(1'-methylpiperidino)-2H-indol-2-one. mp = 210-212°C

3,3-Dimethyl-1-{2-[4-(5-fluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 230°C

55 3,3-Dimethyl-1-{2-[4-(4-fluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one hydrochloride. mp = 235.6-236.6°C

3,3-Dimethyl-1-{2-[4-(5-fluoro-1-methylindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-indol-



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 99 30 3663

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
D,Y	EP 0 780 388 A (LILLY INDUSTRIES LTD) 25 June 1997 (1997-06-25) * page 4, line 1 - line 2; claim 1 *	1-10	C07D401/14 A61K31/44 A61K31/445
Y	PATENT ABSTRACTS OF JAPAN vol. 016, no. 071 (C-0913), 21 February 1992 (1992-02-21) & JP 03 264581 A (DAI ICHI SEIYAKU CO LTD), 25 November 1991 (1991-11-25) * abstract *	1-10	
A	WO 96 23784 A (JANSSEN PHARMACEUTICA NV ;VANDENBERK JAN (BE); KENNIS LUDO EDMOND) 8 August 1996 (1996-08-08) * page 1, line 26 - line 27; claim 1 *	1-10	
A	EP 0 708 102 A (LILLY CO ELI) 24 April 1996 (1996-04-24) * claim 1 *	1-10	
D,A	WO 93 12085 A (ASTRA AB) 24 June 1993 (1993-06-24) * claim 1 *	1	TECHNICAL FIELDS SEARCHED (Int.Cl.6)  C07D A61K
The present search report has been drawn up for all claims			
Place of search <b>MUNICH</b>		Date of completion of the search <b>4 August 1999</b>	Examiner <b>Gettins, M</b>
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document</p> <p>T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &amp; member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 30 3663

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

04-08-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0780388 A	25-06-1997	GB 2308362 A	25-06-1997
		AU 7546096 A	26-06-1997
		BR 9606066 A	01-09-1998
		CA 2193039 A	20-06-1997
		CN 1157822 A	27-08-1997
		CZ 9603722 A	13-08-1997
		HU 9603498 A	28-09-1998
		JP 9202784 A	05-08-1997
		NO 965448 A	20-06-1997
		NZ 299959 A	24-09-1998
		PL 317526 A	23-06-1997
		SG 47206 A	20-03-1998
		TR 970538 A	21-07-1997
		US 5773448 A	30-06-1998
JP 03264581 A	25-11-1991	JP 2860688 B	24-02-1999
WO 9623784 A	08-08-1996	AU 702931 B	11-03-1999
		AU 4664596 A	21-08-1996
		BR 9606815 A	30-12-1997
		CA 2210913 A	08-08-1996
		CN 1172482 A	04-02-1998
		EP 0808313 A	26-11-1997
		FI 973164 A	30-07-1997
		JP 10512893 T	08-12-1998
		NO 973508 A	30-07-1997
		NZ 301264 A	28-07-1998
		PL 321565 A	08-12-1997
EP 0708102 A	24-04-1996	US 5521196 A	28-05-1996
		CA 2159772 A	06-04-1996
		JP 8193082 A	30-07-1996
		US 5721252 A	24-02-1998
WO 9312085 A	24-06-1993	AP 389 A	02-08-1995
		AU 3175993 A	19-07-1993
		BG 98815 A	31-05-1995
		CA 2124826 A	24-06-1993
		CN 1079464 A, B	15-12-1993
		CZ 9401466 A	14-06-1995
		EP 0624156 A	17-11-1994
		FI 942913 A	17-08-1994
		HU 69704 A	28-09-1995
		JP 7502272 T	09-03-1995
		MX 9207382 A	01-07-1993
		NO 942316 A	17-06-1994

EPO FORM P0459


For more details about this annex : see Official Journal of the European Patent Office, No. 12/82



2-one hydrochloride. mp = 194-197°C

# Claims

1. A compound of the formula:



in which n is 1 to 6, m is 1 or 2 and p is 1 or 2,

R<sup>1</sup> and R<sup>2</sup> are each hydrogen, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylthio, halo, optionally substituted phenyl, optionally substituted phenyl-C<sub>1-4</sub> alkyl, or R<sup>1</sup> and R<sup>2</sup> together with the carbon atom to which they are attached form a C<sub>3-6</sub> cycloalkyl group, >C=O, C=NOR' where R' is hydrogen or C<sub>1-4</sub> alkyl,

R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each hydrogen, halo, nitro, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkyl-CO-, where m is 0, 1 or 2, R'R"N-SO<sub>2</sub>-, -COOR', -CONR'R", -NR'R", -N(OR')COOR", -COR', -NHSO<sub>2</sub>R', where R' and R" are each hydrogen or C<sub>1-4</sub> alkyl,

R<sup>6</sup> and R<sup>7</sup> are each hydrogen or C<sub>1-4</sub> alkyl,

X is oxygen or sulphur,

the dotted line represents an optional double bond, and

the fluorine atom is attached at the 6- or 7-position;

and salts thereof.

2. A compound according to Claim 1 in which the fluorine substituent is in the 6-position, and X is oxygen.
3. A compound according to either of Claims 1 or 2 in which the dotted line represents a double bond.
4. A compound according to any of the preceding claims in which m is 2 and p is 1.
5. A compound according to any of the preceding claims in which R<sup>1</sup> and R<sup>2</sup> are each hydrogen, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkylthio.
6. A compound according to any of Claims 1 to 4 in which R<sup>1</sup> and R<sup>2</sup> are both C<sub>1-4</sub> alkyl or benzyl.
7. A compound in which n is 2 and R<sup>6</sup> and R<sup>7</sup> are hydrogen.
8. A pharmaceutical formulation comprising a compound according to any of Claims 1 to 8 associated with a pharmaceutically acceptable diluent or carrier therefor.
9. A compound according to any of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, for use as a phar-

maceutical.

10. The use of a compound according to any of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disorder of the central nervous system.

5

10

15

20

25

30

35

40

45

50

55



**THIS PAGE BLANK (USPTO)**